{"url_path":"/sec/alks/8-k/2026-06-15/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1520262/0001193125-26-270280-index.html","accession_number":"0001193125-26-270280","cik":"0001520262","ticker":"ALKS","issuer_name":"Alkermes plc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1520262/0001193125-26-270280-index.html","primary_entity_key":"0001520262","primary_entity_name":"Alkermes plc."},"word_count":133,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\nOn June 15, 2026, Alkermes plc (the “Company”) issued a press release announcing the grant of orphan drug designations to alixorexton, as described in Item 8.01 of this Current Report on Form 8-K. A copy of the related press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.\n\n \n\nThe information in this Item 7.01, and in Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."}